ClinicalTrials.gg
CompletedNCT03558191Updated Mar 15, 2024Results posted

SHR-1210 in Recurrent/Metastatic Nasopharyngeal Carcinoma Who Have Received Previous At Least Two Lines of Chemotherapy.

A Phase 2 interventional study of SHR-1210 in Nasopharyngeal Carcinoma, sponsored by Jiangsu HengRui Medicine Co., Ltd.. Completed at 1 site in China. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2024-03-15.

Sponsored by Jiangsu HengRui Medicine Co., Ltd. · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
156
Allocation
Not applicable
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 17 studies testing camrelizumab in Nasopharyngeal Carcinoma — 9 open to participants now, 11 under way, 2 of them phase 3. camrelizumab · Nasopharyngeal Carcinoma.

Enrollment
5th of 17
156 · median 58
Started
2018
with 1 other
Phase 2
13 of 17
7 open now
Registered
2nd of 17
by date
Lead sponsor
3 of 17
Jiangsu HengRui Medicine Co., Ltd.

Among the 17 studies testing camrelizumab in Nasopharyngeal Carcinoma, this one is the 5th largest by enrollment, is one of 2 that started in 2018, is one of 13 in phase 2, and was the 2nd registered.

Nasopharyngeal Carcinoma

683 studies on the registry are indexed under Nasopharyngeal Carcinoma; 270 are open to participants now.

Browse Nasopharyngeal Carcinoma studies →

Open to participants now

9 of the 17 studies testing camrelizumab in Nasopharyngeal Carcinoma are open now, in 1 country. Recruiting first, the newest first:

4 more — sign in →

By country, each count listing its studies:

All 9 open studies →

Where they have run

About camrelizumab

No approval found in the FDA or EMA files read. How studies give it is on its page →

Who these studies take

Of the 186 Nasopharyngeal Carcinoma studies recruiting now, 42 (23%) set no upper age limit and 135 (73%) stop at 75 or younger; 9 take children under 18; 8 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 17 studies testing camrelizumab in Nasopharyngeal Carcinoma, or all of them as a file.
02

Study summary

This is an open label, single-arm, multi-center, phase 2 Study of SHR-1210 in recurrent/metastatic nasopharyngeal carcinoma(R/M NPC) patients who have received previous at least two lines of chemotherapy.

Read the detailed description

The primary objective of this phase 2 study is to assess objective response rate of SHR-1210 in patients with R/M NPC. The secondary objective is to observe the duration of response, progression free survival, time to response, overall survival and safety of SHR-1210 in R/M NPC. ADA is also investigated.

03

Conditions studied

  • Nasopharyngeal Carcinoma

Keywords

  • Recurrent/Metastatic Nasopharyngeal Carcinoma
  • PD-1
04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. confirmed Recurrent/ Nasopharyngeal Carcinoma (WHO type II-III);
  2. Stage IVb R/M NPC failed from platinum based chemotherapy and second-line chemotherapy;
  3. performance status of 0 or 1;
  4. ≥ 12 weeks;
  5. Subjects must have by CT or MRI per 1.1 criteria;
  6. Can provide either a newly obtained or sample;
  7. Adequate laboratory parameters during the screening period as evidenced by the following:

    1. ≥ 1.5 × 10\^9/L ;
    2. ≥ 90 × 10\^9/L;
    3. ≥ 9.0 g/dL;
    4. Serum albumin ≥ 2.8g/dL;
    5. Total (TBIL) ≤ 1.5 × (ULN), and AST ≤ 1.5×ULN
    6. ≥50 mL/min;
  8. Female of child bearing potential, a negative urine or serum pregnancy test result within 72 h before study treatment. Participants of must be willing to use adequate for the course of the study through 60 days after the last dose of SHR-1210. Male subjects with partner must be willing to use adequate contraception for the course of the study through 120 days after the last dose of SHR-1210;
  9. Subjects must be willing to participate in the research and sign an form (ICF);

Exclusion criteria

Exclusion Criteria:

  1. Subjects with any active disease or history of autoimmune disease;
  2. Subjects having clinical symptoms of to central nervous system (such as cerebral edema, requiring intervention, or progression);
  3. Has a known additional within the last 5 years before study treatment with the exception of curatively treated basal cell and squamous cell carcinoma of the skin and/or curatively resected in-situ cervical and/or breast cancers;
  4. Uncontrolled heart disease, including but not limited to the following: (1) > II congestive heart failure; (2) unstable angina, (3) myocardial infarction within the past 1 year; (4) clinically significant supraventricular arrhythmia or ventricular arrhythmia requirement for treatment or intervention;
  5. Concurrent medical condition requiring the use of cortisol (>10mg/day Prednisone or equivalent dose) or other systematic medications within 14 days before the study treatment. Except: inhalation or topical corticosteroids. Doses > 10 mg/day prednisone or equivalent for replacement therapy;
  6. Has received prior anti-cancer monoclonal antibody (mAb), chemotherapy, targeted small molecule therapy within 4 weeks prior to first dosing or not recovered to ≤ 1 from adverse events (except for hair loss or neurotoxic sequelae from prior platinum therapy) due to a previously administered agent. Palliative irradiation should be ended 2 weeks before first dosing;
  7. Active infection or an unexplained fever > 38.5°C before two weeks of first dosing (subjects with tumor fever may be enrolled at the discretion of the investigator);
  8. Known (HIV) infection、active or ;
  9. Currently participating or has participated in a study within 4 weeks of the first dose of study medication;
  10. Received a within 4 weeks of the first dose of study medication. Pregnancy or breast feeding;
  11. Received a systematic antibiotics within 4 weeks of the first dose of study medication.

    Pregnancy or breast feeding.

  12. Prior therapy with a , anti-PD-Ligand 1 (PD-L1) or CTLA-4 agent;
  13. Subjects are known to have a history of psychiatric substance abuse, alcoholism, or drug addiction;
  14. Pregnancy or breast feeding;
  15. According to the investigator, other conditions that may lead to stop the research.
Terms in these criteria, in plain language(32)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Line of therapy

A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.

“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

Reproductive potential

Able to have children. For women this usually means from the first period until menopause, unless permanently unable to through surgery; for men, unless permanently sterile. Read who the line is about — participants, women, men, or their partners.

Criteria about it usually ask for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

CTCAE grade

The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.

1
Mild.
2
Moderate.
3
Severe.
4
Life-threatening.
5
Death due to the event.

“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

PD-1, PD-L1 and checkpoint inhibitors

PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.

PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
156 participants (actual)

Study arms

  • Experimental
    SHR-1210 Injection

    SHR-1210 injection, 200 mg/dose, intravenous infusion over 30 minutes, once every 2 weeks .

    Drug: SHR-1210

Interventions

  • A humanized monoclonal immunoglobulin PD-1 antibody

    Also known as: Camrelizumab

06

What researchers measure

Primary outcomes

  1. Objective Response Rate (ORR) Assess by Independent Review Committee (IRC)

    Percentage of participants achieved partial response (PR) or complete response (CR) based on IRC assessment according to the RECIST (version 1.1) is presented for this endpoint. Both CR and PR must be confirmed by repeat assessments performed no less than 4 weeks (28 days) after the criteria for response are first met. Only tumor assessments performed on or before the start date of any further anti-cancer therapies are considered in the assessment of best overall response .

    Time frame: Tumor assessments were conducted at every 8 weeks from the first dose until the end of treatment, withdrawal of consent, or death ,whichever was earlier, approximately 3 years.

Secondary outcomes

  1. ORR Assess by Investigators

    Percentage of participants achieved partial response (PR) or complete response (CR) based on investigator assessment according to the RECIST (version 1.1) is presented for this endpoint. Both CR and PR must be confirmed by repeat assessments performed no less than 4 weeks (28 days) after the criteria for response are first met. Only tumor assessments performed on or before the start date of any further anti-cancer therapies are considered in the assessment of best overall response.

    Time frame: Tumor assessments were conducted at every 8 weeks from the first dose until the end of treatment, withdrawal of consent, or death (whichever was earlier), approximately 3 years.

  2. Duration of Response (DoR)

    DoR is defined, for participants with a CR or PR per RECIST version 1.1, as the time from the first documentation of objective tumor response to the first documentation of objective tumor progression or death, whichever occurs first.

    Time frame: Tumor assessments were conducted at every 8 weeks from the first dose until the end of treatment, withdrawal of consent, or death (whichever was earlier), approximately 3 years.

  3. Disease Control Rate (DCR)

    Percentage of participants achieving PR, CR or SD (SD ≥ 8 weeks) based on IRC assessment according to the RECIST version 1.1 is presented in this endpoint. DCR is a best overall response from the time of first dose to the documented objective progression or the subsequent anti-tumor therapy (whichever occurs first).

    Time frame: Tumor assessments were conducted at every 8 weeks from the first dose until the end of treatment, withdrawal of consent, or death (whichever was earlier), approximately 3 years.

  4. Progression-Free Survival (PFS)

    PFS is defined as the time from the first dose to the date of the first documentation of PD or death, whichever occurs first. PFS was based on investigator assessment according to the RECIST version 1.1. PFS time was summarized using the Kaplan-Meier method.

    Time frame: Tumor assessments were conducted at every 8 weeks from the first dose until the end of treatment, withdrawal of consent, or death (whichever was earlier), approximately 3 years.

  5. Overall Survival (OS)

    Overall Survival is defined as the time from the first dose to death due to any cause. OS time was measured using the Kaplan-Meier method.

    Time frame: Tumor assessments were conducted at every 8 weeks from the first dose until the end of treatment, withdrawal of consent, or death (whichever was earlier), approximately 3 years.

07

Results

Posted Mar 15, 2024

Participant flow

Participant flow — Overall Study
MilestoneSHR-1210 Injection
Started156
Treated156
Completed131
Not completed25

Outcome measures

PrimaryObjective Response Rate (ORR) Assess by Independent Review Committee (IRC)

Percentage of participants achieved partial response (PR) or complete response (CR) based on IRC assessment according to the RECIST (version 1.1) is presented for this endpoint. Both CR and PR must be confirmed by repeat assessments performed no less than 4 weeks (28 days) after the criteria for response are first met. Only tumor assessments performed on or before the start date of any further anti-cancer therapies are considered in the assessment of best overall response .

Time frame:
Tumor assessments were conducted at every 8 weeks from the first dose until the end of treatment, withdrawal of consent, or death ,whichever was earlier, approximately 3 years.
Reported as:
Number · percentage of participants
Objective Response Rate (ORR) Assess by Independent Review Committee (IRC)
percentage of participantsSHR-1210 Injection
Objective Response Rate (ORR) Assess by Independent Review Committee (IRC)28.3 (21.3 to 36.2)
SecondaryORR Assess by Investigators

Percentage of participants achieved partial response (PR) or complete response (CR) based on investigator assessment according to the RECIST (version 1.1) is presented for this endpoint. Both CR and PR must be confirmed by repeat assessments performed no less than 4 weeks (28 days) after the criteria for response are first met. Only tumor assessments performed on or before the start date of any further anti-cancer therapies are considered in the assessment of best overall response.

Time frame:
Tumor assessments were conducted at every 8 weeks from the first dose until the end of treatment, withdrawal of consent, or death (whichever was earlier), approximately 3 years.
Reported as:
Number · percentage of participants
ORR Assess by Investigators
percentage of participantsSHR-1210 Injection
ORR Assess by Investigators24.3 (17.8 to 32.0)
SecondaryDuration of Response (DoR)

DoR is defined, for participants with a CR or PR per RECIST version 1.1, as the time from the first documentation of objective tumor response to the first documentation of objective tumor progression or death, whichever occurs first.

Time frame:
Tumor assessments were conducted at every 8 weeks from the first dose until the end of treatment, withdrawal of consent, or death (whichever was earlier), approximately 3 years.
Reported as:
Median · month
Duration of Response (DoR)
monthSHR-1210 Injection
Duration of Response (DoR)20.3 (13.0 to 30.5)
SecondaryDisease Control Rate (DCR)

Percentage of participants achieving PR, CR or SD (SD ≥ 8 weeks) based on IRC assessment according to the RECIST version 1.1 is presented in this endpoint. DCR is a best overall response from the time of first dose to the documented objective progression or the subsequent anti-tumor therapy (whichever occurs first).

Time frame:
Tumor assessments were conducted at every 8 weeks from the first dose until the end of treatment, withdrawal of consent, or death (whichever was earlier), approximately 3 years.
Reported as:
Number · percentage of participants
Disease Control Rate (DCR)
percentage of participantsSHR-1210 Injection
Disease Control Rate (DCR)54.6 (46.3 to 62.7)
SecondaryProgression-Free Survival (PFS)

PFS is defined as the time from the first dose to the date of the first documentation of PD or death, whichever occurs first. PFS was based on investigator assessment according to the RECIST version 1.1. PFS time was summarized using the Kaplan-Meier method.

Time frame:
Tumor assessments were conducted at every 8 weeks from the first dose until the end of treatment, withdrawal of consent, or death (whichever was earlier), approximately 3 years.
Reported as:
Median · month
Progression-Free Survival (PFS)
monthSHR-1210 Injection
Progression-Free Survival (PFS)3.7 (2.0 to 5.4)
SecondaryOverall Survival (OS)

Overall Survival is defined as the time from the first dose to death due to any cause. OS time was measured using the Kaplan-Meier method.

Time frame:
Tumor assessments were conducted at every 8 weeks from the first dose until the end of treatment, withdrawal of consent, or death (whichever was earlier), approximately 3 years.
Reported as:
Median · month
Overall Survival (OS)
monthSHR-1210 Injection
Overall Survival (OS)18.7 (15.2 to 20.1)

Adverse events

Collected over AEs should be reported from the time the participant has taken at least 1 dose of study treatment through the participant's last visit (approximately 3 years).. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
SHR-1210 Injection11/156 (7.1%)37/156 (23.7%)154/156 (98.7%)
Most frequent serious events
Showing 10 of 37
Most frequent serious events
EventSHR-1210 Injection
progressive diseaseGeneral disorders7/156
epistaxisRespiratory, thoracic and mediastinal disorders4/156
Reactive capillary hyperplasiaImmune system disorders4/156
feverGeneral disorders3/156
pulmonary inflammationRespiratory, thoracic and mediastinal disorders2/156
respiratory failureRespiratory, thoracic and mediastinal disorders2/156
infectious pneumoniaInfections and infestations2/156
Alanine aminotransferase increasedInvestigations2/156
Aspartate aminotransferase increasedInvestigations2/156
upper gastrointestinal hemorrhageGastrointestinal disorders2/156
Most frequent other events
Showing 10 of 53
Most frequent other events
EventSHR-1210 Injection
Reactive capillary endothelial proliferationImmune system disorders140/156
AnaemiaBlood and lymphatic system disorders82/156
CoughRespiratory, thoracic and mediastinal disorders51/156
Aspartate aminotransferase increasedInvestigations47/156
HypothyroidismEndocrine disorders42/156
PyrexiaGeneral disorders39/156
White blood cell count decreasedInvestigations37/156
AstheniaGeneral disorders35/156
HypoalbuminaemiaMetabolism and nutrition disorders31/156
Alanine aminotransferase increasedInvestigations30/156

Baseline characteristics

Age, Categorical
Age, Categorical(Participants)SHR-1210 Injection
<=18 years0
Between 18 and 65 years149
>=65 years7
Sex: Female, Male
Sex: Female, Male(Participants)SHR-1210 Injection
Female32
Male124
Race (NIH/OMB)
Race (NIH/OMB)(Participants)SHR-1210 Injection
American Indian or Alaska Native0
Asian156
Native Hawaiian or Other Pacific Islander0
Black or African American0
White0
More than one race0
Unknown or Not Reported0
Region of Enrollment
Region of Enrollment(participants)SHR-1210 Injection
China156
08

Study locations

1 site
  • Cancer Center of Sun-Yat Sen University (CCSYSU)
    Guangzhou, Guangdong 510060, China
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Aug 2018 to primary completion in Dec 2021, 40 months.

Results were first posted in Mar 2024, 2 years 2 months after primary completion.

Of 143 phase 2 interventional studies under Nasopharyngeal Carcinoma, half reached primary completion within 43 months of starting (the median), counting those still running; a quarter within 28 and three quarters within 65. This study's 40 months is close to that.

How these figures are worked out, and which studies are left out of them.

Registered
May 30, 2018
First posted
Jun 15, 2018
StartActual
Aug 14, 2018
Primary completionActual
Dec 30, 2021
CompletionActual
Dec 30, 2021
Results first posted
Mar 15, 2024
Last update
Mar 15, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 15, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT03558191
Responsible party
Sponsor
First posted
Jun 15, 2018
Start date
Aug 14, 2018
Primary completion
Dec 30, 2021
Completion
Dec 30, 2021
Results posted
Mar 15, 2024
Last update
Mar 15, 2024

Study contacts

Li Zhang, MD
principal investigator · Cancer Center of Sun-Yat Sen University (CCSYSU)
Qing Yang, MD
study director · Jiangsu HengRui Medicine Co., Ltd.

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Apr 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Camrelizumab

Start the discussion